IASIS PHARMA PARTICIPATION ΑΤ ΤΗΕ 3rd PANHELLENIC CONFERENCE OF DERMATOLOGY & VENEROLOGY

28/11/2025|All articles, Product launches, Scientific conferences|

19 - 23/11 2025 Athenaeum InterContinental, Athens During 19 - 23/11 2025, at Athenaeum InterContinental / Athens, the Hellenic Dermatology & Venereology Society together with the Dermatology & Venereology Society of Cyprus organized the 3rd Panhellenic Conference of Dermatology and Venerology. Greek Dermatologists who attended the congress visited IASIS PHARMA exhibition stand to get informed of the IASIS Dermatological [...]

PARTICIPATION OF IASIS PHARMA IN THE “24th PANHELLENIC CONGRESS OF HYPERTENSION”

25/11/2024|All articles, Press Room, Product launches, Scientific conferences|

 07/11 – 09/11 2024 Grand Hyatt/Athens IASIS PHARMA participated in the “24th PANHELLENIC CONGRESS OF HYPERTENSION” which was held from 07/11 to 09/11 2024, at the Grand Hyatt Hotel/Athens. The conference was organized by the Hellenic Society of Hypertension (HSH). IASIS PHARMA presented at its exhibition stand the following products:  RosuZet®: New Product Launching. Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages [...]

NEW PRODUCT LAUNCHING: RosuZet®

22/05/2024|All articles, Company news, Product launches|

IASIS PHARMA is pleased to announce the RosuZet® launching, in the formulation of film-coated tablets. RosuZet® is the fixed dose combination of Rosuvastatin - Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents. RosuZet® [...]

NEW ZYLAPOUR® – ALLOPURINOL PACKAGING: 100 MG x 100 TABS

28/02/2024|All articles, Press Room, Product launches|

IASIS PHARMA is pleased to announce the launch of the new Zylapour® 100 mg x 100 tabs package, which expands the existing Zylapour® 100 mg x 30 tabs & Zylapour® 300 mg x 30 packages. The active substance of Zylapour® is Allopurinol. Allopurinol is in the class of medications called xanthine oxidase inhibitors and it was approved for medical [...]

NEW PRODUCT: CHIOS MASTIHA POWDER – mastiha var. Chia

28/11/2023|All articles, Exploiting the gifts of Greek nature, Press Room, Product launches|

Launching  the new Chios Mastiha in Powder (package of 15 sachets) expands the well-established Mastiha var.Chia brand. Dr. Christos Kon. Zavos, Gastroenterologist – Hepatologist introduced the product to PharmaQ sales force at the new facilities of Iasis Pharma in Koropi. Dr. Christos Kon. Zavos presented all the Updated Facts, Important Scientific Data & Newest Developments [...]

NEW PRODUCT LAUNCH: Qpain®

16/10/2023|All articles, Product launches|

Qpain® is a new topical anti-inflammatory cutaneous solution, containing diclofenac sodium 1.5% w/w, indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee. – Qpain® contains DMSO which enhances the absorption of diclofenac from the skin and reaches the focus of pain and inflammation directly. Ideal for those who cannot [...]

NEW PRODUCT LAUNCHING: Nitrofurantoin/IASIS® oral susp. – 1st Choice, Prevention & Treatment of UTIs

29/06/2023|All articles, Press Room, Product launches|

IASIS PHARMA is pleased to announce the Nitrofurantoin/IASIS oral susp. launching in the oral suspension formulation. This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A. Each 5ml of oral suspension Nitrofurantoin/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature, [...]

NEW PRODUCT LAUNCH: ETROZAC®

20/09/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the release of its new product ETROZAC®. ETROZAC® active substance is etoricoxib which is a selective cox-2 inhibitor. ETROZAC® is indicated for the relief of the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis and the pain and symptoms of inflammation associated with Acute Gout. ETROZAC® is indicated for the [...]

NEW PRODUCT LAUNCH: Rami – Amlo plus®

17/09/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the release of the new product Rami – Amlo plus® Rami – Amlo plus® is an original (prototype) fixed dose combination of Ramipril – Amlodipine -Hydrochlorothiazide Rami – Amlo plus® is indicated for the treatment of hypertension. Available in packs of 30 capsules, in a wide dosage range: Rami [...]

COVED® NEW PRODUCT LAUNCH

23/04/2021|All articles, Product launches|

IASIS PHARMA has successfully launched COVED® to the Greek market. COVED® (Bisphosphonates, combinations) is a fixed dose combination of two active ingredients: Alendronic acid (as alendronate sodium trihydrate) (70mg) & Cholecalciferol (Vitamin D3) (5.600 I.U). COVED® 70 mg / 5,600 IU is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D [...]

Load More Posts